Frontlight ResearchEarly access
Gastric and oesophageal cancer trials in Türkiye
15 trials · From ClinicalTrials.gov, checked 18 November 2026. Ask the study team whether a trial fits you.
- Phase 1/2Taking peopleSubstudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)
- Where
- Adana, Ankara, Erzurum
- Age
- 18 years and over
- People
- 298 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06780111 · EU 2024-514273-22-00 - Phase 3Taking peopleA Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer
- Where
- Adana, Ankara, Bursa, Istanbul, Konya, Samsun, Van
- Age
- 18 years and over
- People
- 500 worldwide
- Run by
- Astellas Pharma Global Development, Inc.
See details and how to joinNCT06901531 · EU 2024-519773-19-00 - Phase 2/3Not yet taking people in TürkiyeA Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)
- Where
- Ankara, Edirne, Kadiköy/Istanbul, Manisa, Sakarya
- Age
- 18 years and over
- People
- 690 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT07221149 · EU 2025-523263-37-00 - Phase 2WithdrawnA Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma
- Where
- Adapazarı, Erzurum, Fatih-Istanbul, Istanbul
- Age
- 18 years and over
- People
- 100 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07069712 · EU 2024-516909-23-00 - Phase 1/2Taking peopleA Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
- Where
- Ankara, Bağcılar, Izmir
- Age
- 18 years and over
- People
- 680 worldwide
- Run by
- Daiichi Sankyo
See details and how to joinNCT06330064 · EU 2023-509632-26-00 - Phase 3Taking peopleA Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer
- Where
- Ankara, Antalya, Diyarbakır, Erzurum, Istanbul, Izmir, Mezitli
- Age
- 18 years and over
- People
- 840 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06764875 · EU 2024-512583-57-00 - Phase 3Not yet taking people in TürkiyeSonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
- Where
- Ankara, Antalya, Istanbul, Medreseboğazı, Şahinbey
- Age
- 18 years and over
- People
- 2,130 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07431281 · EU 2024-519787-40-00 - Phase 3Taking peopleA Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
- Where
- Adana, Ankara, Kuruköprü, Sefaköy
- Age
- 18 years and over
- People
- 351 worldwide
- Run by
- BeOne Medicines
See details and how to joinNCT07043400 · EU 2025-522862-58-00 - Phase 1/2Taking peopleA Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
- Where
- Ankara, Istanbul, Yüreğir
- Age
- 18 years and over
- People
- 1,438 worldwide
- Run by
- BioNTech SE
See details and how to joinNCT07070232 · EU 2024-517261-16-00 - Phase 1/2Taking peopleA Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)
- Where
- Adana, Ankara, Erzurum, Istanbul, Izmir
- Age
- 18 years and over
- People
- 230 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT05319730 · EU 2023-505189-26-00 - Phase 2Taking peopleStudy of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
- Where
- Ankara, Cordaleo, Edirne, Kadıkoy/Istanbul, Konya, Pamukkale, Samsun
- Age
- 18 years to 130 years
- People
- 454 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT05489211 · EU 2023-509436-26-00 - No phaseNot yet taking people in TürkiyeFrailty, Immunonutrition, Surgery Type, and Biologic Recovery in Elderly Gastric Cancer
- Where
- Kocaeli
- Age
- 60 years and over
- People
- 328
- Run by
- Kocaeli City Hospital
See details and how to joinNCT07803159 - Phase 3Taking peopleStudy of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
- Where
- Adana, Ankara, Diyarbakır, Erzurum, Istanbul, Izmir, Samsun
- Age
- 18 years and over
- People
- 726 worldwide
- Run by
- Daiichi Sankyo
See details and how to joinNCT06731478 - No phaseTaking peopleProximal Versus Total Gastrectomy for Locally Advanced Siewert Type II-III Gastroesophageal Junction Cancer
- Where
- Istanbul
- Age
- 18 years to 90 years
- People
- 120
- Run by
- Nurettin Şahin
See details and how to joinNCT07482566 - Phase 3Taking peopleA Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer
- Where
- Adana, Ankara, Diyarbakır, Edirne, Erzurum, Kayseri, Kocaeli, Sakarya, Tekirdağ
- Age
- 18 years and over
- People
- 550 worldwide
- Run by
- Shanghai Henlius Biotech
See details and how to joinNCT06532006 · EU 2024-516633-12-00